研究者業績
  1. 研究者検索結果一覧
  2. 皿井 正義

皿井 正義

マサヨシ サライ  (Sarai Masayoshi)

基本情報

所属
藤田医科大学 医学部 医学科 循環器内科学 病院教授
学位
博士(医学）
J-GLOBAL ID
201501016198481769
researchmap会員ID
7000012705

研究キーワード

 1

研究分野

 1

論文

 105
  • Reina Ozaki, Sadako Motoyama, Yukio Ozaki, Masayoshi Sarai, Hideki Kawai, Tevfik F. Ismail, Wakaya Fujiwara, Keiichi Miyajima, Yasuomi Nagahara, Noriya Uchida, Scot Garg, Naoyuki Kawashima, Yudai Niwa, Hidemaro Takatsu, Yu Yoshiki, Masaya Ohta, Takashi Muramatsu, Masahide Harada, Hiroyuki Naruse, Ayaka Matsui, Haruo Kamiya, Akihiko Tobe, Tsai Tsung-Ying, Yasuko Bando, Yoshinobu Onuma, Hiroshi Takahashi, Hideo Izawa, Patrick W. Serruys, Toyoaki Murohara
    International Journal of Cardiology 421 132895-132895 2025年2月  
  • Ushiroda C., Yamamoto-Wada R., Deguchi K., Tanaka H., Ono C., Yoshida M., Sarai M., Miyahara R., Sasaki H., Iizuka K.
    Nutrients 16(21) 3715 2024年10月  査読有り
  • Yuya Ishihara, Hiroyuki Naruse, Hidetsugu Fujigaki, Reiko Murakami, Tatsuya Ando, Kouhei Sakurai, Komei Uehara, Koki Shimomae, Eirin Sakaguchi, Hidekazu Hattori, Masayoshi Sarai, Junnichi Ishii, Ryosuke Fujii, Hiroyasu Ito, Kuniaki Saito, Hideo Izawa
    Vaccines 12(7) 786-786 2024年7月17日  
    Preexisting cardiovascular disease (CVD) is a pivotal risk factor for severe coronavirus disease 2019 (COVID-19). We investigated the longitudinal (over 1 year and 9 months) humoral and cellular responses to primary series and booster doses of mRNA COVID-19 vaccines in patients with CVD. Twenty-six patients with CVD who received monovalent mRNA COVID-19 vaccines were enrolled in this study. Peripheral blood samples were serially drawn nine times from each patient. IgG against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike receptor-binding domain (RBD) was measured using an enzyme-linked immunosorbent assay. The numbers of interferon-γ-releasing cells in response to SARS-CoV-2 peptides were measured using an enzyme-linked immunospot assay. The RBD-IgG titers increased 2 weeks after the primary series and booster vaccination and waned 6 months after vaccination. The S1-specific T cell responses in patients aged < 75 years were favorable before and after booster doses; however, the Omicron BA.1-specific T cell responses were poor. These results suggest that regular vaccination is useful to maintain long-term antibody levels and has implications for booster dose strategies in patients with CVD. Additional booster doses, including Omicron variant-adapted mRNA vaccines, may be recommended for patients with CVD, regardless of age.
  • Eirin Sakaguchi, Hiroyuki Naruse, Yuya Ishihara, Hidekazu Hattori, Akira Yamada, Hideki Kawai, Takashi Muramatsu, Fumihiko Kitagawa, Hiroshi Takahashi, Junnichi Ishii, Masayoshi Sarai, Masanobu Yanase, Yukio Ozaki, Kuniaki Saito, Hideo Izawa
    Heliyon 10(13) e32452 2024年7月15日  
    The CHA2DS2 -VASc score is a vital clinical tool for evaluating thromboembolic risk in patients with atrial fibrillation (AF). This study investigated the efficacy of the CHA2DS2 -VASc score in a cohort of 737 heterogeneous patients (mean age: 63 years) receiving care in cardiac intensive care units (CICUs), with a creatinine-based estimated glomerular filtration rate (eGFR) of ≥60 mL/min/1.73 m2 upon admission and discharge. Incident chronic kidney disease (CKD) was defined as the emergence of a new-onset eGFR<60 mL/min/1.73 m2, accompanied by a decline of >5 mL/min/1.73 m2 compared to that at discharge. The primary endpoint was the incidence of CKD, and the secondary endpoints included all-cause mortality, cardiovascular events, and progression to end-stage kidney disease. In this cohort, 210 (28 %) patients developed CKD. Multivariate analyses revealed that CHA2DS2 -VASc score was a significant independent predictor of incident CKD, regardless of the presence of AF. Integration of CHA2DS2 -VASc scores with eGFR enhanced the predictive accuracy of incident CKD, as evidenced by the improved C-index, net reclassification improvement, and integrated discrimination improvement values (all p < 0.05). Over the 12-month follow-up period, a composite endpoint was observed in 61 patients (8.3 %), with elevated CHA2DS2 -VASc scores being independently associated with this endpoint. In conclusion, CHA2DS2-VASc scores have emerged as robust predictors of both CKD incidence and adverse outcomes. Their inclusion substantially refined the 12-month risk stratification of patients with preserved renal function hospitalized in the CICUs.
  • Hideki Kawai, Sadako Motoyama, Masayoshi Sarai, Yoshihiro Sato, Takahiro Matsuyama, Ryota Matsumoto, Hiroshi Takahashi, Akio Katagata, Yumi Kataoka, Yoshihiro Ida, Takashi Muramatsu, Yoshiharu Ohno, Yukio Ozaki, Hiroshi Toyama, Jagat Narula, Hideo Izawa
    European radiology 34(4) 2647-2657 2024年4月  
    OBJECTIVES: Evaluation of in-stent restenosis (ISR), especially for small stents, remains challenging during computed tomography (CT) angiography. We used deep learning reconstruction to quantify stent strut thickness and lumen vessel diameter at the stent and compared it with values obtained using conventional reconstruction strategies. METHODS: We examined 166 stents in 85 consecutive patients who underwent CT and invasive coronary angiography (ICA) within 3 months of each other from 2019-2021 after percutaneous coronary intervention with coronary stent placement. The presence of ISR was defined as percent diameter stenosis ≥ 50% on ICA. We compared a super-resolution deep learning reconstruction, Precise IQ Engine (PIQE), and a model-based iterative reconstruction, Forward projected model-based Iterative Reconstruction SoluTion (FIRST). All images were reconstructed using PIQE and FIRST and assessed by two blinded cardiovascular radiographers. RESULTS: PIQE had a larger full width at half maximum of the lumen and smaller strut than FIRST. The image quality score in PIQE was higher than that in FIRST (4.2 ± 1.1 versus 2.7 ± 1.2, p < 0.05). In addition, the specificity and accuracy of ISR detection were better in PIQE than in FIRST (p < 0.05 for both), with particularly pronounced differences for stent diameters < 3.0 mm. CONCLUSION: PIQE provides superior image quality and diagnostic accuracy for ISR, even with stents measuring < 3.0 mm in diameter. CLINICAL RELEVANCE STATEMENT: With improvements in the diagnostic accuracy of in-stent stenosis, CT angiography could become a gatekeeper for ICA in post-stenting cases, obviating ICA in many patients after recent stenting with infrequent ISR and allowing non-invasive ISR detection in the late phase. KEY POINTS: • Despite CT technology advancements, evaluating in-stent stenosis severity, especially in small-diameter stents, remains challenging. • Compared with conventional methods, the Precise IQ Engine uses deep learning to improve spatial resolution. • Improved diagnostic accuracy of CT angiography helps avoid invasive coronary angiography after coronary artery stenting.
もっとみる

MISC

 278

書籍等出版物

 2

講演・口頭発表等

 87
もっとみる

所属学協会

 7
もっとみる

共同研究・競争的資金等の研究課題

 6
もっとみる
一覧へ戻る